Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Health-Related Quality of Life (HRQoL) Assessments in Research on Patients with Adult Rare Solid Cancers: A State-of-the-Art Review

CS. Padilla, CD. Bergerot, K. Dijke, E. Roets, G. Boková, V. Innerhofer, SC. Sodergren, R. Mancari, C. Bergamini, KM. Way, O. Sapoznikov, JA. Burgers, D. Dejaco, MET. Tesselaar, WTA. van der Graaf, O. Husson, EORTC Quality of Life Group

. 2025 ; 17 (3) : . [pub] 20250124

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25008571

Grantová podpora
003-2022 THE EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE GROUP

BACKGROUND: Health-related quality of life (HRQoL) is an important patient-reported outcome for all cancer patients, including adult patients with rare solid cancers. However, current knowledge of HRQoL in this population is limited, which hinders the delivery of personalized care. This review aimed to explore the heterogeneity of HRQoL among adult patients with a solid rare cancer across the ten European Reference Network for Rare Adult Solid Cancers (EURACAN) domains and to summarize the HRQoL measures used in clinical research. METHODS: A systematic literature search was conducted to identify all clinical studies assessing HRQoL in adult patients with a solid rare cancer. Four databases (MEDLINE, PubMed, PsycINFO, and Web of Science/Scopus) were searched (February 2023). RESULTS: The search yielded 18,704 articles, of which 1416 articles were fully screened and 463 were eligible for analysis. Of these, 397 studies used generic tools to assess HRQoL, while 270 used tumor-specific instruments. Three EURACAN domains (sarcoma, endocrine tumors, and thoracic tumors) primarily assessed HRQoL using generic questionnaires. Additionally, the rare gynecological tumor, rare male genitourinary, and sarcoma EURACAN domains lacked specific HRQoL measures. Brain, head and neck, and uveal melanoma EURACAN domains used tumor- or domain-specific questionnaires in more than half of the studies. CONCLUSIONS: This state-of-the-art literature review shows that HRQoL assessment is gradually becoming more prevalent in adult solid rare cancer research. A combination of generic, tumor-specific, and domain-specific questionnaires across various rare cancer domains has proven effective in capturing a broad range of HRQoL issues. However, many EURACAN domains still lack specific strategies for assessing HRQoL, which limits the ability to fully understand and address patients' experiences. Future research should prioritize developing comprehensive and robust HRQoL measurement strategies and tools to enable meaningful clinical research and to ensure that the patient voice is incorporated in their clinical care.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25008571
003      
CZ-PrNML
005      
20250422095635.0
007      
ta
008      
250408s2025 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers17030387 $2 doi
035    __
$a (PubMed)39941756
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Padilla, Catarina S $u Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands $u Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands $1 https://orcid.org/0000000318213760
245    10
$a Health-Related Quality of Life (HRQoL) Assessments in Research on Patients with Adult Rare Solid Cancers: A State-of-the-Art Review / $c CS. Padilla, CD. Bergerot, K. Dijke, E. Roets, G. Boková, V. Innerhofer, SC. Sodergren, R. Mancari, C. Bergamini, KM. Way, O. Sapoznikov, JA. Burgers, D. Dejaco, MET. Tesselaar, WTA. van der Graaf, O. Husson, EORTC Quality of Life Group
520    9_
$a BACKGROUND: Health-related quality of life (HRQoL) is an important patient-reported outcome for all cancer patients, including adult patients with rare solid cancers. However, current knowledge of HRQoL in this population is limited, which hinders the delivery of personalized care. This review aimed to explore the heterogeneity of HRQoL among adult patients with a solid rare cancer across the ten European Reference Network for Rare Adult Solid Cancers (EURACAN) domains and to summarize the HRQoL measures used in clinical research. METHODS: A systematic literature search was conducted to identify all clinical studies assessing HRQoL in adult patients with a solid rare cancer. Four databases (MEDLINE, PubMed, PsycINFO, and Web of Science/Scopus) were searched (February 2023). RESULTS: The search yielded 18,704 articles, of which 1416 articles were fully screened and 463 were eligible for analysis. Of these, 397 studies used generic tools to assess HRQoL, while 270 used tumor-specific instruments. Three EURACAN domains (sarcoma, endocrine tumors, and thoracic tumors) primarily assessed HRQoL using generic questionnaires. Additionally, the rare gynecological tumor, rare male genitourinary, and sarcoma EURACAN domains lacked specific HRQoL measures. Brain, head and neck, and uveal melanoma EURACAN domains used tumor- or domain-specific questionnaires in more than half of the studies. CONCLUSIONS: This state-of-the-art literature review shows that HRQoL assessment is gradually becoming more prevalent in adult solid rare cancer research. A combination of generic, tumor-specific, and domain-specific questionnaires across various rare cancer domains has proven effective in capturing a broad range of HRQoL issues. However, many EURACAN domains still lack specific strategies for assessing HRQoL, which limits the ability to fully understand and address patients' experiences. Future research should prioritize developing comprehensive and robust HRQoL measurement strategies and tools to enable meaningful clinical research and to ensure that the patient voice is incorporated in their clinical care.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Bergerot, Cristiane D $u Psycho-Oncology Services, Oncoclinicas & Co-Medica Scientia Innovation Research (MEDSIR), Sao Paulo 04543-906, Brazil $1 https://orcid.org/0000000300370303
700    1_
$a Dijke, Kim $u Department of Gastrointestinal Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands
700    1_
$a Roets, Evelyne $u Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands $1 https://orcid.org/0000000197337619
700    1_
$a Boková, Gabriela $u International Accreditation Office, Masaryk Memorial Cancer Institute, 7656 53 Brno, Czech Republic $1 https://orcid.org/0009000370501409
700    1_
$a Innerhofer, Veronika $u Department of Otorhinolaryngology-Head and Neck Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria
700    1_
$a Sodergren, Samantha C $u School of Health Sciences, University of Southampton, Southampton SO17 1BJ, UK $1 https://orcid.org/000000018755146X
700    1_
$a Mancari, Rosanna $u Gynaecologic Oncology Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy $1 https://orcid.org/0000000297263653
700    1_
$a Bergamini, Cristiana $u Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy $1 https://orcid.org/0000000176165125
700    1_
$a Way, Kirsty M $u School of Health Sciences, University of Southampton, Southampton SO17 1BJ, UK
700    1_
$a Sapoznikov, Olga $u International Accreditation Office, Masaryk Memorial Cancer Institute, 7656 53 Brno, Czech Republic $1 https://orcid.org/0000000237335352
700    1_
$a Burgers, Jacobus A $u Department of Thoracic Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands $1 https://orcid.org/0000000202188436
700    1_
$a Dejaco, Daniel $u Department of Otorhinolaryngology-Head and Neck Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria $1 https://orcid.org/0000000191767415
700    1_
$a Tesselaar, Margot E T $u Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands $u Department of Gastrointestinal Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands
700    1_
$a van der Graaf, Winette T A $u Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands $u Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands $1 https://orcid.org/0000000175493338
700    1_
$a Husson, Olga $u Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands $u Department of Surgical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands $u Department of Public Health, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands $1 https://orcid.org/0000000213878686
710    2_
$a EORTC Quality of Life Group
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 17, č. 3 (2025)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39941756 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250408 $b ABA008
991    __
$a 20250422095636 $b ABA008
999    __
$a ok $b bmc $g 2306424 $s 1245646
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 17 $c 3 $e 20250124 $i 2072-6694 $m Cancers $n Cancers (Basel) $x MED00173178
GRA    __
$a 003-2022 $p THE EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE GROUP
LZP    __
$a Pubmed-20250408

Najít záznam

Citační ukazatele

Možnosti archivace